|
CBX5 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 3.43359999988024E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.65429999979361E-07 |
| Normal-vs-Stage2 |
1.933960E-01 |
| Normal-vs-Stage3 |
3.02720000000534E-06 |
| Normal-vs-Stage4 |
1.02599999995956E-06 |
| Stage1-vs-Stage2 |
2.599600E-02 |
| Stage1-vs-Stage3 |
6.301600E-01 |
| Stage1-vs-Stage4 |
1.544210E-01 |
| Stage2-vs-Stage3 |
1.967940E-02 |
| Stage2-vs-Stage4 |
4.859000E-03 |
| Stage3-vs-Stage4 |
4.020000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.37500000052526E-07 |
| Normal-vs-AfricanAmerican |
1.463760E-01 |
| Normal-vs-Asian |
4.6634999999462E-06 |
| Caucasian-vs-AfricanAmerican |
6.453700E-02 |
| Caucasian-vs-Asian |
5.638800E-01 |
| AfricanAmerican-vs-Asian |
7.494200E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.034399999995E-05 |
| Normal-vs-Female |
6.20619999947003E-07 |
| Male-vs-Female |
7.347400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
6.86819999984323E-07 |
| Normal-vs-Age(41-60Yrs) |
2.29649999999859E-05 |
| Normal-vs-Age(61-80Yrs) |
1.996250E-04 |
| Normal-vs-Age(81-100Yrs) |
3.138200E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.385600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.948400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.304800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.314200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.012600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.428200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.674100E-02 |
| Classical-VS-Follicular |
5.979600E-01 |
| Classical-VS-Other |
1.502350E-01 |
| Classical-VS-Normal |
3.43989999995742E-06 |
| Tall-VS-Follicular |
1.515950E-02 |
| Tall-VS-Other |
6.600200E-01 |
| Tall-VS-Normal |
6.83100000009595E-07 |
| Follicular-VS-Other |
1.627180E-01 |
| Follicular-VS-Normal |
1.823810E-03 |
| Other-VS-Normal |
5.379000E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.22359999999733E-05 |
| Normal-vs-N1 |
1.82530000003567E-08 |
| N0-vs-N1 |
2.720600E-03 |
|
|
